Incyte Reports Positive Phase 3 Trial Outcomes for Lymphoma Treatment

Incyte has released favorable results from its Phase 3 frontMIND trial for a combination therapy targeting diffuse large B-cell lymphoma. The study demonstrated significant improvements in progression-free survival for patients receiving tafasitamab and lenalidomide alongside standard treatment. These findings were highlighted at a major hematology conference, offering new hope for individuals with this type of cancer.